Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) secured a potentially accelerated regulatory pathway for its experimental antibiotic ibezapolstat after the US Food and Drug Administration (FDA) signaled openness to approving a New Drug Application (NDA) based on a single Phase 3 clinical trial. The outcome of the Type C Meeting held on July 13, 2026, offers the clinical-stage biopharmaceutical company a chance to reduce development timelines and costs, provided the totality of clinical data demonstrates sufficient efficacy and safety for the US market.

The FDA emphasized that the acceptability of a single Phase 3 trial is determined on a case-by-case basis. Key factors include the magnitude, consistency, and overall robustness of efficacy results, as well as the generalizability of those results to the US population and their relevance to US patient care and clinical practice guidelines. The Agency also cited the importance of Phase 2 data and an adequate safety database in making this determination.

Regulatory Criteria and Trial Requirements

The FDA outlined specific conditions under which a single trial would suffice. If the ongoing IBZ-ASPIRE Phase 3 trial meets these rigorous criteria, Acurx may proceed with an NDA submission without conducting a second pivotal study. However, if the IBZ-ASPIRE trial does not satisfy these standards, the Agency recommended that Acurx conduct a second trial consistent with the agreement reached at the end of the Phase 2 (EOP2) meeting on April 27, 2024.

Recurrent CDI Data Support

In addition to the primary Phase 3 pathway, the FDA acknowledged Acurx’s planned clinical trial in recurrent Clostridioides difficile infection (rCDI). The Agency noted that successful data from this rCDI trial would further support an NDA submission, adding another layer of potential evidence for the drug’s approval.

What the Numbers Show

The regulatory flexibility offered by the FDA represents a significant de-risking event for Acurx Pharmaceuticals. By allowing the possibility of a single Phase 3 trial, the Company avoids the substantial capital expenditure and time delay associated with a second pivotal study. This outcome hinges entirely on the performance of the IBZ-ASPIRE trial and the strength of the existing Phase 2 dataset. For investors, this creates a binary near-term catalyst: strong IBZ-ASPIRE results could fast-track approval, while weaker data would trigger the requirement for a second trial as agreed in April 2024.